The 4allele of apolipoprotein E (apoE, protein;
mer' s disease (AD) owing to the increased frequency of the 4 allele in AD (Strittmatter et al., 1993a) . In addition, the cerebral amyloid plaque cores, a major neuropathological feature of AD that contain fibrils of amyloid-/I (A/3) protein, are also immunostained for apoE (Namba et al., 1991; Wisniewski and Frangione, 1992) . Furthermore, in AD patients who are homozygous for the apoE gene (APOE) 4, the amyloid burden in the brain is much greater than in AD patients homozygous for APOE 3 (Rebeck et al., 1993) .
The colocalization of apoE with A/I in amyloid plaque cores suggests an interaction of the latter two molecules. Strittmatter et al. (1993b) demonstrated using purified delipidated human plasma apoE that the E4 isoform bound A/I much more avidly than E3. Thus, it was suggested that E4 may contribute to the pathology of AD by promoting the deposition of A/I. However, subsequent work by LaDu et al. (1994) , using native human recombinant apoE expressed in HEK-293 cells, demonstrated that, in contrast to the previous report, native apoE3 bound A~9more avidly than native E4. The latter authors attributed the different binding patterns observed between the two laboratories to differences in the apoE preparations, which may result in altered conformation of apoE (LaDu et al., 1995) . These data on defective binding of native apoE4 to A~3have recently been confirmed (Zhou et al., 1996) .
The goal of this study was to extend the understand-ing of isoform-specific apoE/A/I binding by characterizing the binding pattern of A/I to native apoE isoforms secreted by transfected cell lines and also to native apoE from human plasma. We confirm that under nondenaturing conditions, the native recombinant apoE3 binds A/I more avidly than E4, and we demonstrate that under similar conditions, apoE2 also binds A/I more avidly than E4. Furthermore, like the apoE isoforms from conditioned media, human plasma native apoE3 bound A/I more avidly than human plasma native apoE4 isoform. Thus, different sources of apoE, provided they are not denatured, may yield apoE of similar protein conformation, which, in turn, may result in similar abilities to form apoE isoform-specific complexes with A/I.
MATERIALS AND METHODS

Materials
A/I 1.40 was prepared at the Keck Foundation Protein Facility at Yale University (New Haven, CT, U.S.A.). The 10-20 or 10% sodium dodecyl sulfate (SDS )/tricine gels and 2x tricine SDS sample buffer were purchased from Novex (San Diego, CA, U.S.A.). Nitrocellulose membranes were from Bio-Rad (Hercules, CA, U.S.A.). Anti-human apoE antibody raised in a goat was purchased from INCSTAR (Stillwater, MN, U.S.A.). Mouse anti-A/I antibody (6E10) was purchased from Dr. K. S. Kim (IBRDD, Staten Island, NY, U.S.A.). Biotinylated rabbit anti-goat or anti-mouse IgG was obtained from Dakopat (Copenhagen, Denmark). Streptavidin-alkalinephosphatase was purchased from Amersham (Buckinghamshire, U. K.), and Fast Red/naphtho! and 5-bromo-4-chloro-3-indolyl phosphate/nitro b!ue tetrazolium were from Sigma (St. Louis, MO, U.S.A.).
Transfected cells
The human APOE 4expression vector was derived from a previously described genomic APOE 1 c!one (Das et a!., 1985) . A Hindlil linker was inserted into the first exon at the unique AatII site at position +24 relative to the start of transcription. DNA extending from this artificial Hindill site to the EcoRI site 628 bp 3' of the APOE polyadenylation site was cloned into pUC 18. A 343-bp PvuII-Hindu! fragment of SV4O, containing the viral early promoter and enhancer, was cloned into the artificial Hindlil site of the APOE plasmid using Hindlil linkers (Smith et al., 1988) . APOE 2 and APOE 3 derivatives were generated by PCR mutagenesis of the APOE 4 expression plasmid and confirmed by DNA sequencing. On day 0, Chinese hamster ovary (CHO) cells were plated in 60-mm-diameter dishes. On day 1, each plate of cells was transfected with 3 ml of serum-free Dulbecco's minimal essential medium containing 12 ml of Lipofectamine (GibcoBRL, Grand Island, NY, U.S.A.), 4 mg of an APOE expression plasmid, and 0.2 mg of pSV2neo (Southern and Berg, 1982) . On day 2, the cells were aspirated and fed with Dulbecco's minimal essential medium containing 10% fetal bovine serum and 800~.tg/ml geneticin (GibcoBRL). Two weeks later, geneticin-resistant colonies were picked, expanded, and assayed for human APOE DNA by PCR specific for the human APOE gene using primers E7 and E9 as previously described (Emi et a!., 1988) . Expression ofhuman APOE mRNA was analyzed by an RNase protection assay (Smith et al., 1990) .
Confirmation of APOE expression by the clonal cell lines
was performed by inimunohistochemistry. Immunohistochemistry for human apoE was performed on adherent cells fixed in methanol for 2 mm; all incubations were performed at room temperature. Cells were treated with casein blocking buffer (Pierce, Rockford, IL, U.S.A.) for 10 mm, followed by a 60-mm incubation with the goat anti-human apoE antiserum (INCSTAR; 1:1,000) in blocking buffer. After washing, the cells were incubated with horseradish peroxidaseconjugated mouse anti-goat IgG (1:250) in blocking buffer for 30 mm. Staining was performed with the 1-Step 4-chloronaphthol reagent (Pierce).
Preparation of conditioned media
ApoE isoform-transfected CHO cells were used to generate conditioned media containing each of the three apoE isoforms: E2, E3, or E4. Transfected CHO cells with an empty vector were used to generate empty vector conditioned media. Media were prepared using Dulbecco's minimal essential medium, which, in some cases, was supplemented with 0.2% (wt/vol) bovine serum albumin. Media were harvested after a 24-h conditioning period. ApoE isoform levels were determined by quantitative immunoblotting of conditioned media and a standard containing human apoE (Calbiochem, La Jolla, CA, U.S.A.).
APOE genotyping
Human plasma specimens from control and AD subjects were also used as a source of apoE. To determine the APOE genotype, DNA was extracted from white blood cells using a standard protocol (Hixson eta!., 1988) . PCR amplification was performed essentially as that described by Hixson and Vernier (1990) using the oligonucleotide primers 5' TCC-AAGGAGCTGCAGGCGGCGCA 3' and 5' ACAGAT-TCGCCCGGCCTGGTACACTGCCA 3', as described by Wenham et a!. (1991) . Genotyping, using PCR followed by restriction enzyme digestion, revealed DNA fragments whose electrophoretic migration pattern was unique for each isotype (Wenham et al., 1991) . Details of APOE genotype distribution of the Australian control and AD population have previously been reported (Martins et al., 1995) .
ApoE/AJ3 binding reactions
For standard binding reactions, recombinant apoE isoforms were each incubated with A/I in phosphate-buffered saline (pH 7.4) in a final concentration of 44~sg/ml apoE and 500~.tg/mlA/I for 5 h at 37°C. The reaction was stopped by adding an equal volume of 2x tricine/SDS sample buffer. For the time course study of binding reactions, samples were aliquoted at different time points, added to an equal volume of 2x tricine/SDS sample buffer, and then frozen at -70°C. The apoE/A/I binding studies on human plasma used 6~sl of plasma (plasma apoE at final concentrations ranging from 4 to 6~.rg/ml) and 25 jig of A/I in a total volume of 50 jil. Plasma apoE and A/I were incubated for 5 h at 37°C.
Western blotting
Recombinant apoE samples were electrophoresed on 10-20% SDS/tricine gels, whereas plasma apoE sources were electrophoresed on 10% SDS/tricine gels and transferred to nitrocellulose membranes. The blotted membranes were incubated in primary antibody for 2 h at room temperature. Both anti-apoE antibody and the A/I monoclonal antibody 6E10 were used at 1:1,000 dilution. Membranes were washed with Tris-buffered saline containing Tween 20 and then incubated with biotinylated secondary antibody (1:2,000 dilution), followed by incubation with strepavidinalkaline phosphatase (diluted 1:2,000). Visualization of specific proteins was achieved by using Fast Red/naphthol or 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.
RESULTS
In an attempt to gain a better understanding of apoE-A/I interactions, we have undertaken studies to assess the binding of A/I to either native apoE isoforms obtained from transfected CHO cells or native apoE from human plasma. We first examined the binding of the three native recombinant apoE isoforms, obtained from transfected CHO cells, with A/I. The apoE isoforms, E2, E3, and E4, migrated in SDS/tricine gel as a 34-kDa protein (Fig. 1, lanes 4, 6, and 8) . When A/I was incubated with these isoforms, both apoE2 and apoE3 formed complexes with A/I as demonstrated by the appearance of a higher-molecular-mass protein (-~38kDa; Fig. 1, lanes 5 and 7) . However, no complex was observed under similar conditions with apoE4 (Fig. 1, lane 9) . Increases in apoE concentrations from 44 to 132 jig/mI did not result in the appearance of apoE4/A/I complexes ( Fig. 2A) . Incubating apoE4
FIG. 2. Recombinant apoE4/A/3 binding reactions and effect of apoE dose (A) and of A/I dose (B).
A: An immunoblot of apoE4/ Aj3 binding reaction mixtures containing A/I (500 jig/mI) with increasing concentrations of apoE4, incubated for 5 h at 37°C and detected with an apoE antibody. Lanes 1-3, 44, 88, and 132 jig/mI, respectively, of apoE4 only; lanes 4-6, apoE4 at 44, 88, and 132 jig/mI, respectively, together with 500 jig/mI A/I. B: An immunoblot of apoE4/A/I binding reaction mixtures containing apoE4 (132 jig/mI) with increasing concentrations of A/I, incubated for 5 h at 37°Cand detected with an anti-apoE antiserum. Lane 1, apoE4 only; lanes 2-5, apoE4 with A/I at 250 jig/ ml, 500 jig/mI, 1 mg/mI, and 2 mg/mI, respectively.
FIG.
3. Time course of recombinant apoE isoform-specific binding to A/I. ApoE/A/3 binding reaction mixtures containing 500 jig/mI A/I and 44 jig/mI apoE were incubated for (A) lh, (B) 1 day, or (C) 4 days at 37°C,probed with an apoE antibody, and immunoblotted. Lane 1, A/I only; lanes 2, 4, 6, and 8, empty vector transfected CHO cell conditioned medium, apoE2, apoE3, and apoE4, respectively; and lanes 3, 5, 7, and 9, A/I incubated with empty vector transfected CHO cell conditioned medium and apoE2, apoE3, and apoE4 conditioned media, respectively.
(132 jig/ml) with increasing A/I concentrations (250 jig/rn! to 2 mg/rn!) did not result in the appearance of apoE4/A/I complexes (Fig. 2B) . The apoE4/A/I complexes were not observed even after longer incubation periods ranging from ito 4 days (Fig. 3) .
Formation of the apoE/A/I complexes of apoE2 and apoE3 was inhibited by addition of the sulfhydryl reducing reagent dithiothreitol (DTT) to the apoE and A/I incubation mixture (Fig. 4A, lanes 7 and 10) or by coincubation with the A/I-specific antibody 4G8 (Fig. 4B, lanes 7 and 10) . ApoE/A/I binding reaction mixtures of A/I (500 jig/mI) with different isoforms ofhuman plasma apoE ( 2/e3,c3/r3, c3/e4, and 4/e4; all isoforms were used at 120 jil of plasma/mI of reaction buffer) were incubated for 24 h at 37°Cand immunoblotted. A and B: Paired blots detected with an anti-apoE antibody and a monoclonal A/I antibody, respectively. Lanes 1, 3, 5, and 7, human plasma only; lanes 2, 4, 6, and 8, both human plasma and A/I. ApoE/A/I complexes were also formed when human plasma was used as a source of apoE. The major 40-kDa complex was visualized with both the antiapoE antibody and the A/I-specific antibody 6E10 for three APOE genotypes, 2/ 3, e3/e3, and e3/ 4 (Fig.  5, lanes 2, 4, and 6 ), but not for the 4/ 4 genotype (Fig. 5, lane 8) . Again, complex formation could be inhibited with either DTT or by coincubating apoE and A/I together with an apoE-speciflc antibody (data not shown). In addition to the 40-kDa complex, two other apoE/A/I complexes were detected. A 34-kDa apoE/ A/I complex was observed with the two antibodies in all the above four genotypes studied (Fig. 5, lanes 2,  4, 6, and 8) . A 43-kDa complex was detected with the 6E10 antibody in all the above four genotypes (Fig.  SB, lanes 2, 4, 6 , and 8); it was also detected with the anti-apoE antibody in the 2/ 3, 3/ 3,and 3/ 4 genotypes (Fig. 5A, lanes 2, 4, and 6) but not in the 4/ 4genotype (Fig. 5A, lane 8) . This protein is unlikely to be an apoE/A/I complex for the 4/ 4geno-type because it was not detected by the anti-apoE antibody.
Time course studies revealed that apoE/A/I complex formation was observed for apoE3 as early as 10 mm following incubation at 37°C (Fig. 6A) . On the other hand, apoE/A/I complex formation was not observed until 1 h when plasma apoE4 was used as a source of apoE and then only for the lower-molecular-mass 34-kDa complex observed (Fig. 6B) . After incubation of apoE4 and A/I for 24 h, a 43-kDa protein was also detected with the A/I antibody (Fig. 6B ).
DISCUSSION
Our results obtained with apoE from conditioned media are in agreement with an earlier report of LaDu et al. (1994) in that native apoE3 binds A/I avidly. These authors observed a 20-fold difference between the level of apoE3 IA/I complex and the apoE4IA/I complex. In our study, we were unable to detect any apoE4/A/I complex formation under various conditions using the CHO-derived native apoE4 isoform. This lack of detectable binding to A/I by recombinant apoE4 is consistent with an earlier report by some of us using stably transfected RAW264 macrophage cells as a source of apoE (Zhou eta!., 1996) . We also report here that a 40-kDa human plasma apoEIA/I complex was detected in all APOE genotypes except for APOE 4 homozygotes. Taken together, our results confirm previous reports that the various sources of native recombinant apoE exhibit qualitatively similar isoformspecific A/I binding patterns. Furthermore, this study extends these findings to demonstrate that these isoform-specific A/I binding patterns are also observed with human plasma apoE where apoE4 is the only isoform that does not form a 40-kDa apoE/A/I complex.
The density of A/I deposition is directly related to inheritance of an 4 allele (Schmechel et a!., 1993) . This increased A/I deposition in AD brains for APOE 4-containing individuals appears to contradict the in vitro data presented here where apoE4 binding to A/I was markedly decreased or not detected at all under our conditions. However, this discrepancy may be explained by apoE3 efficiently binding A/I and clearing it from the extracellular space; conversely, the inability of apoE4 to bind A/I efficiently results in the accumulation of A/I in the extracellular space leading to its deposition. Thus, the increased deposition of A/I in brains of AD patients with an 4 allele would suggest inefficient clearance of A/I by this isoform of apoE.
It is possible, however, that apoE4 may behave differently in the CNS compared with its counterpart in plasma. The lipid associated with apoE in the CSF has not been thoroughly characterized but is thought to be different from the lipid associated with apoE in plasma.
FIG.
6. Time course of human plasma apoE isoform-specific binding to A/I. ApoE/A/I binding reaction mixtures of A/I (500 jig/mI) with human plasma apoE (e3/e3 and e4/ 4 at 120 jil of plasma/mi) were incubated at 37°Cfor 2 mm, io mm, i h, 5 h, and 24 h (lanes 1-5, respectively) and immunoblotted. The apoE/A/I complexes were detected with the A/I-specific monoclonal antibody 6E10.
It is therefore important to investigate, in future studies, the CSF apoE isoform-specific binding pattern to A/I to get a better understanding of the role of apoE4 in AD.
In summary, unpurified, native recombinant apoE showed marked isoform-specific differences with respect to binding A/I, consistent with previous reports using apoE from transfected cells. In all these studies, including our own, apoE3 bound A/I avidly, whereas apoE4 bound A/I poorly or not at all. In addition, we report for the first time that apoE2 binds A/I just as avidly as apoE3. These findings were consistent with subsequent experiments when human plasma was used as a source of native apoE. This is the first report, to our knowledge, demonstrating a 40-kDa apoE/A/I complex in all genotypes except for APOE 4 homozygotes. Furthermore, the slower formation of the 34-k.Da plasma apoE/A/I complexes in APOE 4homozygotes together with a complete lack of formation of the 40-kDa complex demonstrates that native human plasma apoE4 binds A/I poorly under the conditions used in this study. Our results are consistent with the view that apoE4 may exert its risk factor effects in AD by inefficient clearance of A/I. However, further studies are required to determine whether human CSF apoE forms similar apoE isoform-specific apoE/A/I complexes as has been demonstrated in this study for both human plasma and recombinant apoE isoforms.
